Osseointegrative effect of rhBMP-2 covalently bound on a titan-plasma-spray-surface after modification with chromosulfuric acid in a large animal bone gap-healing model with the Göttingen minipig by Lingner, Manuel et al.
Lingner et al. Journal of Orthopaedic Surgery and Research  (2018) 13:219 
https://doi.org/10.1186/s13018-018-0915-xRESEARCH ARTICLE Open AccessOsseointegrative effect of rhBMP-2
covalently bound on a titan-plasma-
spray-surface after modification with
chromosulfuric acid in a large animal
bone gap-healing model with the
Göttingen minipig
Manuel Lingner1,2, Roland Seidling1,2, Lars Johannes Lehmann1,3, Eckhard Mauermann1,4, Udo Obertacke1
and Markus Ludwig Rupert Schwarz1*Abstract
Background: Bone morphogenetic proteins play an important role as osseointegrative factors. It is used widely in
orthopedic research and surgery to enhance the osseointegrative potential of implants, e.g., in spinal fusion or
alveolar socket augmentation. The aim of the present study was to investigate the benefit of rhBMP-2 on a titan
plasma spray (TPS) layer after a special modification with chromosulfuric acid (CSA) at different postoperative times,
regarding osseoconduction and osseoinduction.
Methods: We allocated 27 Göttinger minipigs into three groups consisting of nine animals each. They received
four dumbbell-shaped implants in the metaphyseal parts of the femora. The implants had a TPS surface with (CSA
group) and without a CSA treatment (TPS group). The former received an additional layer of BMP-2 (BMP-2 group).
For the assessment of osseointegration after healing periods of 4, 8, and 12 weeks, histomorphometry was applied
to undecalcified specimens after staining according to Masson-Goldner. An intravital labeling with different
fluorochromes was used in the gap model. A multivariable analysis with repeated measurement design was
performed for statistical evaluation.
Results: We observed several statistical differences in a three-way ANOVA. The comparison between the BMP-2 and
the TPS group (two-way ANOVA) showed statistically significant differences in terms of the osseoinduction (osteoid
volume), and pronounced for the osseoconduction (bone and osteoid ongrowth), in favor of the BMP-2 group. In the
pairwise comparison between BMP-2 and CSA (two-way ANOVA), no statistical significance occurred. The intravital
staining with tetracycline, calcein green, and xylenol orange revealed no considerable differences between the groups.
Conclusion: BMP-2, covalently bound on a CSA-treated TPS surface, has positive effects on the osseointegration in the
large animal bone gap-healing model over the observation period of 12 weeks.
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Bone morphogenetic proteins play an important role in
the proliferation, differentiation, and induction of mes-
enchymal stem cells as well as in the embryogenesis [1].
BMP-2, currently one of the best-studied bone morpho-
genetic proteins, is applied increasingly in orthopedic
surgery [2]. The working group of Jennissen developed a
method for the surface modification which allows a sub-
sequent biocoating by proteins, e.g., BMP-2 [3]. The
basis of this principle underlies the production of an
ultra-hydrophilic surface on titanium implants with
chromosulfuric acid, which leads to a so-called inverse
lotus effect, which causes a reduction of the contact
angle to < 10° [4]. The procedure has already been pub-
lished several times in detail and is patented [3, 5–8]. By
the addition of anchor molecules, BMP-2 can be bound
and retains its biological activity [6, 9]. Thus, the pre-
requisite for adequate protein binding is the prior treat-
ment with chromosulfuric acid. Previous studies showed
that the treatment with chromosulfuric acid alone has
an osseointegrative potential [10]. BMPs as differenti-
ation factors are suspected to promote malignant degen-
eration when used in humans [11].
Gap models have been used since 1980 and earlier
in orthopedic research, allowing the investigation of
bone repair under special conditions with different
questions [10, 12–15].
The animal of our choice, the Göttingen minipig, has
been proven to be a reliable animal for examining im-
plants, especially because of the similar characteristics of
the mesenchymal stem cells [16], as well as because of a
comparable lamellar bone structure [17].
Histomorphometry, as well as the polychrome label-
ing, finds application in the evaluation of bone re-
modeling processes [10]. For fluorescence microscopy,
in the sense of intravital staining, combinations of dif-
ferent fluorochromes lead to a better resolution of os-
sification fronts by synergistic effects [18], and this
could be shown, e.g., for tetracycline and xylenol or-
ange [19]. For some substances, no spectral analysis
is needed, which would require an immense effort for
the evaluation [20, 21].
The gold standard in orthopedic research is the histo-
morphometry, particularly for the assessment of osseoin-
tegration, which allows a quantitative assessment on the
basis of an established standardized nomenclature since
the 1980s [22–24].
The aim of the study was to investigate the
osseointegrative force of different titanium surfaces
at different postoperative times in respect to a cova-
lently bound layer made of BMP-2 additionally. The
application in an animal bone gap-healing model
should reveal the potential for osseoinduction and
osseoconduction.Methods
The animal study was approved by the ethical commit-
tee of the Regierungspräsidium Karlsruhe, Abteilung 3 -
Landwirtschaft, Ländlicher Raum, Veterinär - und
Lebensmittelwesen, Karlsruhe, Germany, under the file
no. 35-9185.81/G-27/05.
Preparation of implants
Cylindrical dumbbell-shaped implants were used with a
total length of 30 mm, a gap length of 15 mm, and a
resulting gap after implantation with a height of approxi-
mately 1.28 mm as reported by Seidling et al. [10]. The
surface structure was created on one hand, by the appli-
cation of titanium plasma spray (TPS group), and on the
other hand, by modification with a chromosulfuric acid
alone (CSA group) and subsequent covalently bound
rhBMP-2 (BMP-2 group). This method was developed
and patented by the working group of Jennissen (Univer-
sity of Duisburg-Essen) [3, 7]. The modification is car-
ried out by a treatment with chromosulfuric acid for
60 min at high temperature and subsequent cleaning
with EDTA and water [3, 25]. This process leads to an
ultra-hydrophilic surface by thickening the oxide layer
with improved binding capacity [4]. After this treatment,
BMP-2 can be covalently bound stable to the surface
and retains its biological activity [25, 26].
The titan implants with the TPS layer in the middle part
were produced by the company DOT (Rostock, Germany)
and described in more details by Seidling et al. [10]. Modi-
fied in the manner described above, they were provided
sterile and ready for implantation by the working group of
Jennissen (University of Duisburg-Essen) and the com-
pany Morphoplant GmbH (Duisburg, Germany).
Animals and surgery
Twenty-seven Göttinger minipigs (Ellegaard, Dalmose,
Denmark) were divided into three groups with nine ani-
mals each. In the TPS group, the animals had an average
weight of 64.72 kg (SD ± 6.26 kg). In the CSA group, the
average weight was 59.5 kg (SD ± 13.85 kg), and in the
BMP-2 group, the average weight was 56 kg (SD ±
14.69 kg). The animals were on average 37.7 months old
in the mean (SD ± 4.66 months). Thus, the animals were
adults, as Christensen had reviewed [27].
We observed a time period of 4, 8, and 12 weeks post-
operatively for each group; so, the animals were accord-
ingly divided into three further subgroups.
Each animal received four implants as described previ-
ously by Seidling et al. [10]. The implants were im-
planted on both sides, in the cancellous bone of the
distal and proximal part of the femur strictly press-fit
and under general anesthesia according to Schwarz et al.
[28, 29]. Pre- and postoperative monitoring and housing
of the animals were performed in the “Interfakultäre
Table 2 Scores for the polyfluorochrome labeling
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University of Heidelberg (Germany) up to 14 days post-
operatively. They were held for the followed healing
period on a farm near Heidelberg until to a few days be-
fore the scheduled time point of killing. The animals
were fed with “Schweine-Einmastkorn” (17% crude pro-
tein) of the company Muskator (Mannheim, Germany).
Water was available at any time ad libitum. The animals
survived the operation procedure, and there were no
perioperative obvious complications observed.
Intravital staining
For the semiquantitative evaluation of the osseointegra-
tion, an intra-vital staining was performed with the sub-
stances calcein green (20 mg/kg; Fa. Pfizer, Karlsruhe/
Germany), xylenol orange (90 mg/kg; Fa. Waldeck
GmbH&CoKG, Münster/Germany), and tetracycline
(26 mg/kg; Fa. Waldeck GmbH&CoKG Münster/
Germany) [30], according to the scheduled time of appli-
cation (Table 1) [10]. The substances were administered
by injection into the neck muscles of the animals in the
postoperative period.
Implant separation and preparation
The animals were killed in deep sedation after pre-
medication at the scheduled postoperative time of 4, 8,
or 12 weeks, by injection of 20–40 ml KCL 7.45% under
strict ECG control. The death was ascertained by asys-
tole, auscultation, and a missing corneal reflex. The pro-
cedure is described by Seidling et al. [10]. Shortly
summarized, the preparation of the undecalcified sam-
ples was performed according to Donath and Breuner
which is a method for embedding and processing of jaw
bones with teeth or bone with ceramic and metal im-
plants [31]. A modified Masson-Goldner staining was
used to differentiate between mature bone and immature
osteoid [32]. The sample selection and preparation pro-
cedure has already been described by Seidling et al. [10]
and Lehmann et al. [33] previously. In particular, the
very middle specimen of the serial cuts was used.
Evaluation
The histomorphometric evaluation was carried out inter-
actively using a Leica DRC 300 FX-microscope (Fa. Leica
Camera AG, Solms, Germany). For this study, a specific
evaluation program (“Macro”) has been created with theTable 1 Day of injection and postoperative period for the
fluorochromes
Postoperative time Tetracykline Xylenol orange Calcein green
4 weeks Day 9 Day 16 Day 24
8 weeks Day 37 Day 44 Day 52
12 weeks Day 65 Day 72 Day 80Leica company based on the Leica Qwin V3 software
(Leica Camera AG, Solms, Germany) [10]. This allows a
computer-based assessment on the basis of mosaic im-
ages of the complete gap under higher magnification.
The samples were sighted on the microscope while using
the semiautomatic evaluation program and marking the
different types of bony tissues namely osteoid and bone
respectively. The created Macro has been validated pre-
viously [34]. The variables of bone and osteoid ongrowth
as indicators for the osseoconduction, as well as bone
and osteoid volume as indicators for the osseoinduction,
were able to be determined due to the use of the stain-
ing according to Masson-Goldner [10, 32].
All slides were checked and then blinded prior to the
histomorphometrical evaluation by three independent
investigators (ML, RS, EM). A ROI of 5 mm width in
the middle of the gap was used according to the prior
investigation. All non-evaluable preparations were sorted
out. As exclusion criteria, e.g., a partial gap coverage and
surface detachment of the TPS surface layer were identi-
fied [10]. The evaluators repeated measurements on a
specific specimen for self-supervision [10].
For the microscopic evaluation with a Leica DRC 300
FX (Leica Camera AG, Solms/Germany; used filters:
LeicaI3 = DAPI/Leica N2.1 = Rhodamin/Leica A = FITC)
of the polyfluorochrome labelling, semi-quantitative
scores were used, which are represented by means of a
subjective assessment of the activity in general as an
overview (general score), the amount of the observed
fluorescence quantitatively for the de novo bone forma-
tion (amount score), and the intensity of the observed
fluorescence for the bone turnover (intensity score) [10].
Table 2 shows the scores used and their assessment.
Statistics
The data was prepared in cooperation with the Depart-
ment for Medical statistics, Biomathematics, and Infor-
mation Processing, Medical Faculty Mannheim of the
University of Heidelberg.
The four relevant outcomes of this trial were osteoid
ongrowth, bone ongrowth, bone volume, and osteoid vol-
ume. Due to the non-normal distribution of the prepara-
tions (Kolmogorov test) and missing of homoscedasticity
in a Levene’s test, the data experienced a logarythmizationPoints General score Amount score Intensity score
0 None No bone None
1 Uncertain Minor Very low intensity
2 Minor Moderate Minor
3 Much Much Moderate
4 X X Much
5 X X Very much
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10 (bone ongrowth and osteoid ongrowth). After this
transformation, data revealed to be approximately nor-
mally distributed with similar variances in the subgroups.
With these data, analysis of variance (ANOVA) with
repeated measurement design was performed using SAS
release 9.4 (SAS Institute, Cary / North Carolina, USA).
The SAS procedure “PROC MIXED” has been applied
for two- or three-way ANOVAS where the parameters
group (“type of implant”), localization (hip or knee), and
postoperative time (4, 8, and 12 weeks) have been con-
sidered as fixed factors and animal ID as a random fac-
tor. We used these techniques in order to analyze three
factors simultaneously and to test for interactions. If ne-
cessary, pairwise post hoc comparisons have been done
using Tukey’s test.
For the statistical evaluation of the intravital staining,
only a descriptive statistics was carried out using Excel
for Mac Version 2011 (Microsoft Company, Washing-
ton/USA). The level of significance was α = 0.05. A sam-
ple size calculation was performed as described by
Seidling et al., previously [10].Results
Amount of implants
In total, 95 implants of 108 were able to be evaluated. At
least 9 implants of 12 were able to be assessed in one
CSA group and one BMP-2 group. Implants were lost in
several groups due to the defined exclusion criteria.
The following line-up of the three-way ANOVA and
the pairwise comparison between the groups BMP-2,
TPS, and CSA give a closer look at the results.BMP-2 vs. TPS
The three-way ANOVA showed significant differences
for the variables bone ongrowth (implant type), osteoid
volume (implant type), and osteoid ongrowth (implant
type and postop time) in the pairwise comparison be-
tween TPS and BMP-2 (Table 3).
After a healing period of 4 weeks, there was an increased
amount of osteoid in the gap, shown by the variable of oste-
oid volume with mean values of 5.13% (SD ± 2.58%) for co-
valently bound BMP-2 vs. 1.89% (SD ± 0.85%) for the TPSTable 3 The calculated p values of the three-way ANOVA of the com
of significance is 0.05; “*” shows significant values)
Bone volume Ost
Implant type 0.2143 0.0
Postoperative time 0.8643 0.4
Location 0.0682 0.1
Implant type x postoperative time 0.3327 0.5
Implant type x location 0.1945 0.7layer. The remaining values of osseoinduction showed post
hoc no significant difference (Fig. 1).
After 4 weeks, there was significantly more bone to
implant contact, expressed by the variable bone
ongrowth, with a p value of 0.0281 (BMP-2 2.47% ±
2.63% vs. TPS 0.01% ± 0.03%). Also after 8 weeks, we ob-
served an increased bone to implant contact with a p
value of 0.0431 (BMP-2 9.71% ± 9.25% vs. TPS 0.53% ±
1.34%) (Fig. 2). After a healing period of 12 weeks, there
was no significant difference (Fig. 2).
For the osteoid to implant contact, we observed a statis-
tically significant increase over the whole observation
period (Fig. 2). After a healing period of 4 weeks, we found
an increased osteoid ongrowth with amounts of 4.32%
(SD ± 4.34%) for BMP-2 vs. 0.15% (SD ± 0.26%) for TPS.
After a healing period of 8 weeks, we observed an in-
creased contact of osteoid to the implant with amounts of
7.81% (SD ± 5.82%) for BMP-2 vs. 0,46% (SD ± 1.08%) for
TPS. We also observed an increased amount after a period
of 12 weeks with 13.59% (SD ± 13.44%) for BMP-2 and
1.18% (SD ± 1.74%) for TPS (Fig. 2).CSA vs. BMP-2
The three-way ANOVA showed significant differences
for the variables bone volume (location) and osteoid
ongrowth (postoperative time) in the pairwise compari-
son between CSA and BMP-2 as shown in Table 4. The
post hoc test for the interaction between implant type
and postoperative period give a closer look on the
osseointegration.
For the osseoinduction, expressed by the variables
bone and osteoid volume, in the pairwise comparison
between the CSA group and the BMP-2 group, there
was no statistically significant difference seen over the
complete observation period of until 12 weeks as shown
in Fig. 3.
There was 1.7 to threefold more osteoid in contact to
the implant in favor of BMP-2. No statistically significant
differences could be shown after the 4, 8, and 12 weeks
of healing period. Also, there was a 2.9 to 3.9-fold more
bone to implant contact in the BMP-2 group, but there
was also found no significant difference after a healing
period of 4, 8, and 12 weeks. In a nutshell, there was noparison BMP-2 vs. TPS using the “PROC MIXED” of SAS 9.4 (level
eoid volume Bone ongrowth Osteoid ongrowth
324* 0.0012* < 0.0001*
614 0.1823 0.0352*
151 0.1050 0.9518
861 0.3799 0.2299
746 0.2297 0.2944
ab
Fig. 1 Comparison of the BMP-2 group and the TPS group for osseoinduction. a Osteoid volume and b bone volume by group (BMP-2 vs. TPS)
and postoperative duration (4, 8, and 12 weeks). Only for the amount of osteoid in the gap, a significant difference was able to be shown
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CSA and the BMP-2 group (Fig. 4).
Implant location
In the contemplation of the implantation site (hip vs.
knee) within the BMP-2 group over the postoperative
periods of 4, 8, and 12 weeks, there was additionally a
significant difference found for the variable bone volumewith a p value of 0.0496 in favor of the hip localization
with mean values of 6.87% (SD ± 4.94%) for the location
knee and 10,54% (SD ± 4.91%) for the hip.
Intravital staining
We observed bone turnover over the whole postoperative
period of 12 weeks. There was an inconsistently but slight
bone turnover, dependent on the used score (Fig. 5).
ab
Fig. 2 Comparison of the BMP-2 group and the TPS group for osseoconduction. a Osteoid ongrowth and b bone ongrowth by group (BMP-2 vs.
TPS) and postoperative duration (4, 8, and 12 weeks). For the osteoid to implant contact, expressed by the variable osteoid ongrowth, a
significant difference between BMP-2 and TPS over the whole observation period was able to be shown, in favor of BMP-2. After 4 and
8 weeks, there was significantly more bone to implant contact (bone ongrowth) in the BMP-2 group with no statistically significant
difference after 12 weeks
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Table 4 The calculated p values of the three-way ANOVA of the comparison BMP-2 vs. CSA using the “PROC MIXED” of SAS 9.4 (level of
significance is 0.05; “*” shows significant values)
Bone volume Osteoid volume Bone ongrowth Osteoid ongrowth
Implant type 0.9213 0.7129 0.3260 0.2602
Postoperative time 0.5053 0.1498 0.0627 0.0081*
Location < 0.0001* 0.1140 0.0927 0.9597
Implant type x postoperative time 0.4037 0.3262 0.5878 0.7636
Implant type x location 0.2097 0.7716 0.5963 0.3977
Lingner et al. Journal of Orthopaedic Surgery and Research  (2018) 13:219 Page 7 of 13Depending on the score used, we found relatively small
differences between TPS and BMP-2 to the max. 17%
(quantity score), with relatively large variances (up to 49%
of the mean value).
Discussion
The aim of the study was to evaluate the osseointegra-
tive force of rhBMP-2 in a large animal.
We have seen the main effect in the formation of oste-
oid and bone at the surface of the implant less inside the
gap. And the effect of the BMP-2 protein seems to be
pronounced more for the growth of osteoid as a precur-
sor of bone than at mature bone. Seen from a temporal
perspective, one can assume that the appearance of oste-
oid is close to the recruitment of preosteoblasts. In the
present study, we found an indication of new osteoid
formation at the beginning after 4 weeks which we inter-
pret as osteoinduction. This can be correlated to the ex-
planations of Albrektsson and Johannson [35]. They
point out that the osteoinduction may start immediately
after injury (in the present study the implantation) with
a high activity over the first weeks as the recruitment of
preosteoblasts may not be evident until some weeks
later. This may explain also our results that we did not
see any further effects in the gap in terms of osteoinduc-
tion later on.
Several chemotactic properties have been demon-
strated for BMP-2 which is discussed as responsible for
attracting corresponding effector cells [36–39]. Presum-
ably, this property contributes to the influence of osteo-
conduction after long-term fixation of the BMP-2 to
surfaces [5]. Since the significant differences were found
mainly in the immature bone-like osteoid volume and
osteoid ongrowth in the present study, it can be as-
sumed that the effects of BMP-2 have not yet been com-
pletely assessed as the observation time was limited to
12 weeks. Further investigations should be performed to
show effects at a later time.
The used BMP-2 coating was covalently bound to the
titanium TPS surface by prior treatment with chromo-
sulfuric acid and binding via anchoring molecules and
maintains a contact angle of 0–8° for 50 days [25]. The
biological activity is reported as still evident [25] shown
in cell culture by detection of alkaline phosphatase as anindicator of bone induction by BMP-2. Thus, the results
of the present study can close the gap between in vitro
and in vivo assessment together with preliminary studies
with the same bioactive layer [40]. Sumner and co-
workers made a study to analyze the influence of differ-
ent dosage of BMP-2 on top of a HA/TCP. They found
a 2–3.5-fold increase of bone formation in the gap which
was 3 mm in height [13]. They compared a previously
reported group with HA/TCP to recent groups with lo-
cally delivered rhBMP-2 in the left humeri and implants
with solely buffer in the right humeri. Effects on the
contralateral site were observed with an enhanced bone
ingrowth. So, Sumner and colleagues hypothesized that
not the BMP-2 but rather factors released by the regen-
eration process are responsible for this reported contra-
lateral effect. Thus, a systemic effect could be discussed
using BMP-2 as implant coating. In the present study,
the control groups were separate pigs with only BMP-2
or CSA modification or none (TPS). Thus, an effect on
control implants which were set in the same animal was
excluded by the study design in the present trial.
As previously described, the implanted specimens
were subjected to a treatment with chromosulfuric acid
at high temperatures prior to biocoating with BMP-2 via
anchor molecules, a process known as “surface enhance-
ment” [41]. It has already been shown that this has a
positive effect on osseoinduction as well as on osseocon-
duction [10, 40]. This effect, however, appears to be
higher after addition of BMP-2. But, the present results
show markable differences between BMP-2 covalent and
CSA, which are all not significant post hoc. Considering
the results of the paired comparison of CSA and TPS in
particular as described by Seidling and coworkers [10],
significant differences were seen for the variables osteoid
ongrowth and (12 weeks) osteoid volume (4 weeks).
Thus, the effect does not appear to be due solely to the
surface modification.
The used gap model allows the differentiation be-
tween the osteoinductive and the osteoconductive
properties of a layer on an implant in the bone [10].
Gap models are known as models for healing and turn-
over research in bone [14, 42, 43]. It is also known as a
model to examine some sealing effects between the im-
plant and bone [12] when a gap results between the
ab
Fig. 3 Comparison of the BMP-2 group and the CSA group for osseoinduction. a Osteoid volume and b bone volume by group (BMP-2 vs. CSA)
and postoperative duration (4, 8, and 12 weeks). No statistically significant difference was able to be shown in the pairwise comparison of BMP-2
and CSA for the variables bone and osteoid volume
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be filled by bone. A sealing effect can also be an im-
portant feature of a BMP-2 coating in primary treat-
ment with artificial joints or even with revision surgery
when a loss of the bone stock came up and gaps be-
tween implant and bone are likely [10, 44, 45]. At theother hand, a gap could be seen as a carrier system like
a potential reservoir between implant and bone for
BMP enhancing osteogenesis, e.g., for the treatment of
nonunions after bone fractures by local delivery of the
protein [46, 47]. We additionally observed a significant
difference for the implant site (hip vs. knee) and the
ab
Fig. 4 Comparison of the BMP-2 group and the CSA group for osseoconduction. a Osteoid ongrowth and b bone ongrowth by group (BMP-2 vs.
CSA) and postoperative duration (4, 8, and 12 weeks). There was no statistically significant difference between the groups BMP-2 and CSS to be
shown for the bone or osteoid-to-implant contact by the pairwise comparison
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what extent, there is an interaction between the site of
implantation (knee or hip) and the surface could only
be observed. Since it was not content of the presentstudy, further observations are needed to clarify this
observation.
Proteins need appropriate carrier systems when
bound at the surface of an implant to keep their
ab
c
Fig. 5 Intravital staining by postoperative period for the a general score, b intensity score, and the c amount score. The error indicators
correspond to the standard deviations
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techniques are described [49]. The specific technique
for bonding the BMP-2 at the TPS surface of the
used implants is described by Jennissen and hisgroup [3, 41] and was performed in the present
study.
Beneath the choice of the appropriate time point the
gap model may have disadvantages for the analysis of
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implants. The BMPs were detected when the bone was
implanted into the tissue like the musculus rectus ab-
dominis or quadriceps or in bone [50]. Looking at the
situation in the gap model where alloplastic material is
used at the implant site blood supply has to be missed
in consequence.
A perfect animal for all types of bone research may
not exist as there is a high variation in, e.g., bone
turnover [51]. Especially in small animals, the bone
turnover seems to be much higher than in humans or
large animals [51]. As previously described, the lamel-
lar bone structure of Göttingen minipigs is nearly
similar to humans, as well as the remodeling se-
quences [17, 52]. Furthermore, the bone marrow and
marrow stem cells of Göttingen minipigs have similar
characteristics to humans, especially in proliferation
and morphology [16]. Not least, there is a high ex-
perience with this type of animals in orthopedic re-
search, and they are cost-effective and easy to handle
[53]. Nevertheless, none of the common study ani-
mals like dogs, pigs, or rats is fully comparable with
humans [52].
The analysis of the intravital staining revealed bone
turnover over the whole observation time. None of the
used scores was able to distinguish between the BMP-2
and the TPS group clearly as the values laid close together
combined with wide standard deviations for both groups.
The wide variances may also be caused by the differing re-
sults of the examinations of the three observers (data not
shown) reflecting the individual character of the evalu-
ation. However, the activity of bone turnover was not con-
stant in the scores over the observation time. The “general
score” and the “amount score” seemed to diverge at the
end of the observation time, whereas the “intensity score”
shows an undulating behavior.
However, the semi-quantitative nature of the assess-
ment must be considered. In particular, the used scores
are highly dependent on the investigator. Furthermore,
the light-emitting behavior of the substance in the
mineralization front is quite different and depends above
all on the processing and handling of the preparations
[20]. Pautke et al. [20] observed no bleaching effect for
the substances xylenol orange, calcein green, and
rolitetracycline during storage in the dark and room
temperature over a period of 6 months. Only the sub-
stance calcein blue showed a disappearance of the
fluorochrome effect after 6 months [20]. Due to the ex-
perimental setup, the temporal distance between im-
plantation and evaluation was more than 6 months; so, a
bleaching cannot be safely excluded. Comparing both
techniques, the histomorphometry and the intravital
staining, we guess that the histomorphometry is more
effective than the intravital staining in the assessment ofosseointegration of implants, not least because of the
low intra- and interobserver reliability.
In general, some drawbacks of BMP-2 have to be con-
sidered when used. According to the basic characteristic
of the protein, ectopic bone formation may be possible
after implantation in some case reports we have found
in literature [54–57]. However, the working group of the
present study was able to exclude a side effect in this
case in terms of new bone formation at another site of
the treated animals [33].
A review, published by Carragee et al. [11], brought
BMP-2 into disrepute in the application to humans. Car-
ragee et al. described a clear study design bias with an
actually 10–50-fold increased complication rate com-
pared to the previously published data [11]. There was a
40% increased risk of adverse events compared to the
conventional autologous bone graft, as well as an in-
creased risk of malignant disease in the absence of bene-
fit of the BMP-2 [11, 58, 59]. Since rhBMP-2 is a
derivative of a differentiation factor in the mesenchymal
development, malignant degeneration is not unlikely [54,
60]. A participation in tumor angiogenesis, as well as an
inhibition of tumor cell apoptosis, could also be demon-
strated [39].
Thus, the harmlessness of BMP-2 should be shown in
further studies as this question was not the rationale of
the present study dealing with the osseointegration.
Conclusion
Covalently bound BMP-2, applied to a titanium sample
body after prior surface modification with chromosulfu-
ric acid, had positive effects on the osseointegration in
the large animal model during the observation period of
12 weeks. The osseoconduction, expressed by the vari-
ables osteoid ongrowth and bone ongrowth, was mainly
influenced. Due to the lack of significant differences in
the pairwise group comparison between BMP-2 and
CSA, further studies should show a benefit of the
BMP-2 against the sole surface modification even more
clearly. The results showed that the effect is probably
not explainable by the treatment with chromosulfuric
acid solely rather by an additional application of BMP-2.
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